Please assess the completion status of the following clinical trial:

Trial Title: Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mycosis fungoides~  * Stage IB or IIA~ * Confirmed by current or prior diagnostic lesion biopsy~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* Karnofsky 60-100%~Life expectancy~* Not specified~Hematopoietic~* WBC at least 2,000/mm\^3~* Hemoglobin at least 9 g/dL~Hepatic~* Bilirubin no greater than 1.5 times upper limit of normal (ULN)~* AST and ALT no greater than 2.5 times ULN~Renal~* Creatinine no greater than 2 times ULN~* Calcium no greater than 11.5 mg/dL~Cardiovascular~* No New York Heart Association grade III or IV cardiac insufficiency~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after study participation\* NOTE: \*Women using hormonal contraception must also use a non-hormonal treatment~* Fasting triglycerides normal (prior antilipemic agents allowed to reach normalization)~* Willing and able to avoid prolonged exposure to the sun~  * Willing to limit sun exposure on day of PUVA therapy~* No prior intolerance of or unresponsiveness to PUVA therapy~* No other prior or concurrent malignant tumor except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer~* No prior pancreatitis~* No other concurrent serious illness or infection that would preclude study participation~* No concurrent excessive alcohol consumption~* No photosensitivity due to intrinsic (e.g., lupus) or extrinsic (e.g., photosensitive drugs) factors~* No psychological, familial, sociological, or geographical condition that would preclude study compliance~* No known contraindications to study drug~* No known hypersensitivity to retinoids or hypervitaminosis A~* No uncontrolled diabetes mellitus~* No uncontrolled thyroid disease~PRIOR CONCURRENT THERAPY:~Biologic therapy~* At least 3 months since prior interferon therapy~Chemotherapy~* No prior systemic combination chemotherapy~* No prior participation in another study of bexarotene~* At least 3 months since prior topical chemotherapy~Endocrine therapy~* At least 1 month since prior topical corticosteroids~Radiotherapy~* At least 6 months since prior total skin electron beam therapy~* At least 1 month since prior superficial radiotherapy~Surgery~* Not specified~Other~* At least 30 days since prior participation in another investigational drug study~* At least 3 months since prior photopheresis~* At least 1 month since prior UVB/PUVA phototherapy~* At least 1 month since prior retinoid class drugs~* At least 1 month since prior beta-carotene compounds~* At least 1 month since other prior topical medications (e.g., tar baths)~* No prior participation in this study~* No other concurrent anticancer therapy~* No other concurrent investigational drug therapy~* No concurrent drugs associated with pancreatic toxicity or known to increase triglyceride concentrations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Bexarotene and PUVA (Type: EXPERIMENTAL): None
- PUVA (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues